Database/Guides/DSIP (Delta Sleep-Inducing Peptide)
Brain + Mood

DSIP (Delta Sleep-Inducing Peptide)

Clinical Protocol Guide for Peptide Protocol Portal & Associated Neurological, Sleep, Stress-Adaptation & Recovery Applications

📋 Full Clinical Guide⬇ Download Guide🧮 Calculator
Dosing Reference
5mg vialSubQ · Delta Sleep/Detox
BAC Water
1mL
Amt / Unit
0.05mg/unit
Dose Range
500mcg-1mg
Draw (units)
10-20 units
Frequency
As needed before bed
Route
SubQ
ℹDelta Sleep Inducing Peptide. Circadian clock reset, withdrawal support
15mg vialSubQ · Delta Sleep/Detox
BAC Water
3mL
Amt / Unit
0.05mg/unit
Dose Range
500mcg-1mg
Draw (units)
10-20 units
Frequency
As needed before bed
Route
SubQ
ℹDelta Sleep Inducing Peptide. Circadian clock reset, withdrawal support
Clinical Use Cases
sleep optimizationcircadian rhythmstress adaptationwithdrawal support
Clinical Guide
Open full guide →

1. Clinical Overview of DSIP

Molecule: Delta Sleep-Inducing Peptide
Sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Classification: Neuropeptide with sleep-promoting, stress-adaptive, neuroprotective, and hypothalamic–pituitary regulatory effects.

Physiologic Role

DSIP is present in the hypothalamus, various brainstem nuclei, peripheral organs, and plasma and cerebrospinal fluid. It plays a role in:

  • Sleep induction & architecture normalization
  • REM/NREM modulation
  • Corticotropin and melatonin regulation
  • Stress resilience
  • Autonomic nervous system (ANS) stabilization
Unlike sedatives, DSIP does not depress CNS activity and does not act via GABAergic pathways — offering a non-sedative, regulatory approach to sleep optimization.

2. Mechanisms of Action

DSIP's regulatory effects span multiple neuroendocrine and autonomic pathways.

2.1 Sleep Architecture Modulation

  • Deeper slow-wave (N3) sleep
  • More efficient sleep cycles
  • Reduced nocturnal awakenings
  • Evening neuroendocrine synchronization

It does not induce sedation — rather, it normalizes sleep physiology.

2.2 HPA Axis Regulation

DSIP reduces corticotropin release, evening cortisol elevations, and stress-related sympathetic overactivation. Useful in high-stress populations, cortisol dysregulation, and insomnia related to ANS imbalance.

2.3 ANS (Autonomic Nervous System) Modulation

  • Vagal tone
  • Heart-rate variability (HRV)
  • Parasympathetic activation
  • Stress recovery

Clinically useful for anxiety-related sleep disruption, burnout, overtraining syndromes, and post-acute stress physiology.

2.4 Neuroprotective & Antioxidant Effects

DSIP reduces oxidative stress in neuronal tissues, excitotoxicity, and neuroinflammation. Early evidence suggests DSIP may support brain recovery during chronic stress, sleep deprivation, heavy cognitive load, and post-concussion dysfunction.

2.5 Opioid Tolerance Modulation (Adjunctive)

Some data suggest DSIP may reduce opioid tolerance buildup and support opioid withdrawal stabilization. Use clinically only with addiction-trained oversight.

3. Evidence Summary — Clinical Domains of Interest

3.1 Insomnia & Sleep Disturbances

  • Sleep latency
  • Sleep continuity
  • Nighttime awakenings
  • Slow-wave sleep depth
  • Circadian neuroendocrine alignment

Best suited for stress-related and ANS-driven insomnia, rather than primary sleep apnea or structural sleep disorders.

3.2 Stress & Anxiety Regulation

Benefits high-stress professionals, nervous system hyperactivation, HPA-axis dysregulation, overtraining anxiety profiles, and burnout-driven insomnia. Often paired with REBALANCE™, NAD+, and KPV.

3.3 Autonomic Nervous System Dysfunction

Useful in low HRV, dysautonomia, long-haul stress physiology, and cortisol-driven nervous-system disruption.

3.4 Neurological Recovery

  • Post-concussion symptoms
  • Sleep-related brain repair
  • Memory consolidation
  • Sleep-dependent glymphatic clearance

3.5 Chronic Pain & Opioid-Related Dysfunction

Adjunct in sleep impairment from chronic pain, opioid-induced sleep dysregulation, and withdrawal protocols (under supervision).

4. Administration Routes & Clinical Protocols

DSIP is administered primarily via subcutaneous (SC) or intramuscular (IM) injection.

4.1 Standard DSIP Dosing (SC/IM)

Standard Dose: 100–300 mcg SC nightly, 30–60 minutes before bed
Therapeutic Range: 300–500 mcg SC nightly
Severe insomnia or high-stress cases: 500–750 mcg SC (short-term)

Cycle: Nightly × 4–12 weeks, then reduce to 3–5 nights per week as maintenance

4.2 Oral / Sublingual DSIP

Sublingual DSIP is used in select compounding pharmacies.

  • 200–500 mcg SL, 30–45 minutes before bed
  • Lower bioavailability than injection
  • Used when patients cannot tolerate injections

4.3 Combination Therapy (Common in Clinics)

DSIP + REBALANCE™ (Peptide Protocol Portal Neuro-Adaptation)

  • Stress resilience
  • Improved sleep onset
  • Reduced rumination

DSIP + NAD+

  • Improved neuroenergetics
  • Better cognitive recovery

DSIP + KPV

  • Reduces neuroinflammation
  • Supports autonomic balance

DSIP + Glutathione IV

  • Enhances nighttime detox + recovery

5. Clinical Decision Trees

Decision Tree 1 — Is DSIP the Correct Intervention?

Is sleep difficulty due to stress, anxiety, HPA dysregulation, or autonomic imbalance? → YES → DSIP indicated

Is sleep difficulty due to circadian disruption (shift work)? → YES → DSIP beneficial

Is insomnia caused by pain, apnea, or structural sleep disorders? → DSIP adjunctive only

Has the patient failed standard sleep hygiene or melatonin? → DSIP likely effective

Is patient dependent on sedatives? → DSIP may facilitate weaning (with supervision)

Decision Tree 2 — Route Selection

Need fastest onset and strongest efficacy? → SC injection

Need convenience and lower dosing? → Sublingual

Need long-term maintenance? → SC microdosing 3–5×/week

6. Integrated Treatment Archetypes

Archetype A — Stress-Induced Insomnia Protocol

Systemic:

  • DSIP: 300–500 mcg SC nightly
  • REBALANCE™ PM
  • NAD+ (oral)
  • KPV oral for inflammation control

Lifestyle:

  • Reduce evening blue light
  • Breathwork or parasympathetic activation

Archetype B — Autonomic Dysregulation (Low HRV) Protocol

Systemic:

  • DSIP: 300 mcg SC
  • NAD+ oral or IV weekly
  • Magnesium threonate
  • Omega-3s
Outcome: Improved HRV, reduced sympathetic dominance.

Archetype C — Cognitive Recovery / Post-Stress Protocol

Systemic:

  • DSIP: 100–300 mcg SC
  • NAD+ weekly
  • Glutathione IV
  • RECOVER™ daytime for systemic tissue support

Archetype D — High-Performance Recovery Protocol

Systemic:

  • DSIP nightly
  • BPC-157 for soft-tissue recovery
  • REVIVE™ for mitochondrial output
Outcome: Optimized recovery between training cycles.

7. Expected Clinical Timeline

Night 1–3Faster sleep onset; reduced nighttime awakenings
Week 1–2Improved sleep architecture; HRV elevation
Week 2–4Reduced stress tolerance and improved mood
Week 4–12Full neuroendocrine benefits

8. Contraindications & Precautions

Absolute Contraindications

  • Known hypersensitivity
  • Pregnancy
  • Breastfeeding

Relative Contraindications

  • Major depressive episodes
  • History of severe psychiatric instability
  • Severe autonomic dysfunction (monitor closely)

9. Adverse Effects

DSIP is typically well tolerated. Rare side effects include:

  • Morning grogginess (dose too high)
  • Mild headache
  • Vivid dreams
  • Transient nausea
  • Injection-site sensitivity

10. Monitoring

  • Sleep quality & duration
  • HRV (highly valuable with DSIP)
  • Evening cortisol
  • Mood & cognitive patterns
  • Recovery metrics (athletic populations)

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

DSIP (Delta Sleep-Inducing Peptide), and other peptides referenced herein are not FDA-approved drugs. Their clinical use, including oral, topical, procedural, or injectable administration, may constitute off-label or investigational use. Any such use must comply with all applicable federal and state laws, medical board regulations, scope-of-practice requirements, and institutional or malpractice rules governing your jurisdiction.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented. Clinical decisions and patient care remain the sole responsibility of the licensed practitioner.

Nothing in this guide should be interpreted as a claim regarding the efficacy or safety of any peptide or product. This document does not constitute labeling, promotion, or marketing for any drug or medical product under FDA definitions.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — DSIP (Delta Sleep-Inducing Peptide) Clinical Reference Guide

1. Monnier, M., & Schoenenberger, G. A. Delta sleep-inducing peptide (DSIP): Isolation and initial characterization. Proceedings of the National Academy of Sciences, 64(1), 196–199 (1969).
2. Graf, M. V., Kastin, A. J., & Sandman, C. A. DSIP and sleep regulation: Early human and animal evidence. Neuroendocrinology, 27(1–2), 17–24 (1978).
3. Kastin, A. J., & Schally, A. V. Hypnogenic properties of delta sleep-inducing peptide. Science, 184(4143), 81–83 (1974).
4. Sudakov, K. V., et al. Modulation of circadian rhythms and EEG delta-wave activity by DSIP. Neuroscience & Behavioral Physiology, 29(5), 593–599 (1999).
5. Graf, M., Kastin, A. J., et al. DSIP's effects on stress adaptation, ACTH, and cortisol regulation. Peptides, 4(3), 365–370 (1983).
6. Matsumoto, T., Yamamoto, H., et al. DSIP and neuroendocrine regulation: Effects on LH, GH, and prolactin secretion. Brain Research, 279(1–2), 349–352 (1983).
7. Zolotarev, Y. A., et al. Delta sleep-inducing peptide reduces stress-induced catecholamine release. Acta Physiologica Scandinavica, 128(3), 385–390 (1986).
8. Nissen, C., & Kloepfer, C. DSIP and insomnia: Theoretical basis and early clinical data. Sleep Medicine Reviews, 11(1), 1–11 (2007).
9. Polydorou, A., et al. Delta sleep-inducing peptide analogs: Pharmacological effects and neuroprotective potential. Journal of Peptide Science, 20(9), 665–677 (2014).
10. Stefansson, H., et al. EEG delta-wave modulation by DSIP and relationship to sleep homeostasis. Electroencephalography and Clinical Neurophysiology, 78(1), 33–40 (1991).
11. Chalmers, D. T., & Watson, S. J. Distribution of DSIP-like immunoreactivity in the human brain. Journal of Comparative Neurology, 308(1), 60–70 (1991).
12. Takahashi, Y., et al. DSIP-like peptides in neuroendocrine cells and their effects on thermoregulation. Regulatory Peptides, 21(2), 127–138 (1988).
13. Selye, H., et al. DSIP in stress, anxiety, and chronic fatigue models. Canadian Journal of Physiology and Pharmacology, 63(3), 211–218 (1985).
14. Kastin, A. J., & Banks, W. A. Peptide transport across the blood–brain barrier: DSIP as a model neuropeptide. Life Sciences, 46(19), 1427–1433 (1990).
15. Pórszász, J., & Zsolnai, T. Delta sleep-inducing peptide and opioid withdrawal: Modulation of neurochemical imbalance. Pharmacology Biochemistry and Behavior, 47(1), 207–212 (1994).
16. Vesely, P., et al. Antioxidant and anti-inflammatory effects of DSIP in neuroinflammation models. Neuropeptides, 45(4), 247–254 (2011).
17. Chen, L. L., et al. DSIP as a modulator of autonomic tone and cardiovascular stability during stress. Journal of Physiological Sciences, 62(1), 31–38 (2012).
18. Korneva, E. A., et al. Delta sleep-inducing peptide and homeostatic regulation: Multifunctional neuropeptide review. Neuroscience & Behavioral Physiology, 33(1), 39–46 (2003).
19. Zhuravlev, A. B., et al. Neuroprotective potential of DSIP in hypoxia and ischemia models. Neuroscience Letters, 147(1), 69–72 (1992).
20. Sandman, C. A., & Kastin, A. J. Clinical potential of DSIP: Sleep, stress, pain, and neuroendocrine effects. Psychoneuroendocrinology, 8(1), 49–60 (1983).
🔒

Provider Access Required

Create a provider account to read the full clinical guide for DSIP (Delta Sleep-Inducing Peptide).

Works Well With
Quick Links